Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Evoke Pharma, Inc.

A specialty pharmaceutical company focused on developing treatments for patients living with gastrointestinal diseases.

Evoke Pharma

Evoke Pharma is a Biotechnology company located in 420 Stevens Avenue, Suite 230, Solana Beach, California, 92075                United States

Square 1 Bank

Latterell Venture Partners

Domain Associates

#EVOKUpdates — Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Join us on April 24th at 12:00 PM ET for our online KOL and investor webinar moderated by Yale Jen, Ph.D, Senior Managing Director of Equity Research at Laidlaw Capital Markets. The event will feature Dr. Michael Cline, Medical Director of the Cleveland Clinic's gastroparesis clinic. 

🔍 Key Highlights:
Expert Insights: Dr. Cline will share his expertise on the rising incidence of gastroparesis linked to GLP-1 medications and the patient experience with GIMOTI®.

In-Depth Discussion: Explore current data on healthcare resource utilization related to GIMOTI® and learn how it's shaping the future of gastroparesis treatment.

Register here: https://lnkd.in/ddhStUr5.

Full announcement: https://lnkd.in/d_3SHpV3. 

Got questions? Please email dboateng@dkbpartners.net to have them answered during the webinar.

#EvokePharma #Gastroparesis #FightDGP #GIMOTI

#EVOKUpdates - Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

"Halfway into 2024, as prescriptions continue to grow, we are executing on our distribution expansion strategy and are seeing improved growth trajectory of access and sales for GIMOTI. The combination of the shift to ASPN and the expansion of additional regional pharmacies is yielding results to help unlock GIMOTI's true market potential," stated Matt D'Onofrio, Chief Executive Officer of Evoke Pharma.

Please view the full announcement here: https://lnkd.in/eMw8wMTn.

#EVOK #gastroparesis #GIMOTI

Happy New Year! Here are some insights we noticed in Gastroenterology & Endoscopy News to kick the year off, the results of a newly published study link popular oral GLP-1 agonists such as Ozempic and WeGovy to serious GI adverse events (AEs) such as gastroparesis and pancreatitis. 

Underscoring the implications of these potential AEs,  Dr. Eduardo Grunvald, Director of the Weight Management Program at UC San Diego Health, told Gastroenterology & Endoscopy News, “These adverse events are rare but given the potential number of people that will use them, absolute numbers of serious adverse events will not be trivial.”

At Evoke, we are continuously enabling the availability of GIMOTI, our novel metoclopramide nasal spray solution for the treatment of acute and recurrent gastroparesis in adults. 

Read the full G&E article here: https://lnkd.in/dSax7szG.

#FightDGP #EVOK #Gastroparesis

#EVOKUpdates — United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

“We continue to witness the significance of GIMOTI in the marketplace through various validation points, including patient and market data, growing revenues, and a robust stream of patent protections. We are thrilled to continue providing patients a life-changing experience with diabetic gastroparesis treatment and bolster the already promising commercial opportunity for GIMOTI,” commented Matt D'Onofrio, President and COO of Evoke Pharma.

Please read the full announcement here: https://lnkd.in/gv6fQmKz. 

#EVOK #IP #FightDGP

What a time to be at #ACG2023! Our team and EVERSANA are on the ground, connecting with the esteemed professional community at ACG. Stop by our booth and our presentation on Wednesday if you're in attendance! 

#EVOK #FightDGP #GIMOTI

🎉 Needless to say, Digestive Disease Week® (DDW) 2024 was a success! 🎉

We had an amazing time connecting with our passionate commercial team, talented physicians, and the incredible community of GI experts. It was a pleasure showcasing GIMOTI and sharing insights with such an energetic and dedicated crowd.

Already counting down to next year! ✨


#DDW2024 #GIMOTI #Gastroparesis #EVOK

NASDAQ:EVOK

Evoke Pharma

Last Close

5.56

08/11 21:00

Market Cap

4.94M

Beta: 0.37

Volume Today

174.05K

Avg: 18.86K

PE Ratio

−0.30

PFCF: −0.37

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics